[go: up one dir, main page]

WO2003057881A1 - Method of stabilizing protein - Google Patents

Method of stabilizing protein Download PDF

Info

Publication number
WO2003057881A1
WO2003057881A1 PCT/JP2002/013804 JP0213804W WO03057881A1 WO 2003057881 A1 WO2003057881 A1 WO 2003057881A1 JP 0213804 W JP0213804 W JP 0213804W WO 03057881 A1 WO03057881 A1 WO 03057881A1
Authority
WO
WIPO (PCT)
Prior art keywords
stabilizing protein
antibody
deamidation
asparagine
inhibited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/013804
Other languages
English (en)
French (fr)
Inventor
Izumi Sugo
Kikuo Tomonou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to EP21173914.9A priority Critical patent/EP3960855A1/en
Priority to EP02792048A priority patent/EP1464702A4/en
Priority to US10/500,184 priority patent/US20050171339A1/en
Priority to JP2003558175A priority patent/JP4063769B2/ja
Priority to AU2002362197A priority patent/AU2002362197A1/en
Priority to EP19185595.6A priority patent/EP3604523A1/en
Publication of WO2003057881A1 publication Critical patent/WO2003057881A1/ja
Anticipated expiration legal-status Critical
Priority to US11/508,070 priority patent/US8084584B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/JP2002/013804 2001-12-28 2002-12-27 Method of stabilizing protein Ceased WO2003057881A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP21173914.9A EP3960855A1 (en) 2001-12-28 2002-12-27 Method for stabilizing proteins
EP02792048A EP1464702A4 (en) 2001-12-28 2002-12-27 METHOD FOR PROTEIN STABILIZATION
US10/500,184 US20050171339A1 (en) 2001-12-28 2002-12-27 Method of stabilizing protein
JP2003558175A JP4063769B2 (ja) 2001-12-28 2002-12-27 タンパク質安定化方法
AU2002362197A AU2002362197A1 (en) 2001-12-28 2002-12-27 Method of stabilizing protein
EP19185595.6A EP3604523A1 (en) 2001-12-28 2002-12-27 Method for stabilizing proteins
US11/508,070 US8084584B2 (en) 2001-12-28 2006-08-22 Methods for stabilizing proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-400895 2001-12-28
JP2001400895 2001-12-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10500184 A-371-Of-International 2002-12-27
US11/508,070 Continuation US8084584B2 (en) 2001-12-28 2006-08-22 Methods for stabilizing proteins

Publications (1)

Publication Number Publication Date
WO2003057881A1 true WO2003057881A1 (en) 2003-07-17

Family

ID=19189694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/013804 Ceased WO2003057881A1 (en) 2001-12-28 2002-12-27 Method of stabilizing protein

Country Status (5)

Country Link
US (2) US20050171339A1 (ja)
EP (3) EP3604523A1 (ja)
JP (2) JP4063769B2 (ja)
AU (1) AU2002362197A1 (ja)
WO (1) WO2003057881A1 (ja)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006315964A (ja) * 2005-05-10 2006-11-24 Chugai Pharmaceut Co Ltd 抗体安定化方法
JP2009545325A (ja) * 2006-08-04 2009-12-24 アストラゼネカ アクチボラグ ＥｒｂＢ２に対する抗体
EP2216046A2 (en) 2004-07-09 2010-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
WO2010131733A1 (ja) * 2009-05-15 2010-11-18 中外製薬株式会社 抗axl抗体
US7867734B2 (en) 2004-10-26 2011-01-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US7871613B2 (en) 2004-08-24 2011-01-18 Chugai Seiyaku Kabushiki Kaisha Adjuvant therapy with the use of anti-glypican 3 antibody
WO2012057288A1 (ja) * 2010-10-29 2012-05-03 第一三共株式会社 新規抗ｄｒ５抗体
WO2012133782A1 (ja) * 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
JP2013521769A (ja) * 2010-03-11 2013-06-13 ユセベ ファルマ ソシエテ アノニム 生物学的製剤：ヒト化アゴニスト抗ｐｄ−１抗体
WO2013100120A1 (ja) 2011-12-28 2013-07-04 中外製薬株式会社 ヒト化抗Epiregulin抗体および当該抗体を有効成分として含む癌治療剤
WO2014208482A1 (ja) 2013-06-24 2014-12-31 中外製薬株式会社 ヒト化抗Ｅｐｉｒｅｇｕｌｉｎ抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9102739B2 (en) 2005-10-14 2015-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
US9175091B2 (en) 2007-11-15 2015-11-03 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US10005832B2 (en) 2009-05-29 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Method for treating a disease originated from receptor activation by EREG and TGFα
JP2019502670A (ja) * 2015-12-04 2019-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌の治療のための新規抗体
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10253100B2 (en) 2011-09-30 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
WO2019114804A1 (zh) 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 一种EGFRvIII抗体及其偶联物、制备方法和应用
US10618965B2 (en) 2011-02-25 2020-04-14 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US10782300B2 (en) 2012-12-21 2020-09-22 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
JP2023531625A (ja) * 2020-06-19 2023-07-25 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ＣＤ３及びＦｏｌＲ１に結合する抗体
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
US11820793B2 (en) 2011-11-30 2023-11-21 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2024034638A1 (ja) * 2022-08-10 2024-02-15 協和キリン株式会社 抗ｆｇｆ２３抗体又は該抗体断片
US12269876B2 (en) 2012-02-09 2025-04-08 Chugai Seiyaku Kabushiki Kaisha Modified Fc region of antibody

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100022454A1 (en) * 2006-10-03 2010-01-28 Novo Nordisk A/S Peptides with High Affinity for the Prolactin Receptor
AU2008232903B9 (en) * 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
EP2167059A2 (en) * 2007-07-05 2010-03-31 Novo Nordisk A/S Novel prolactin compounds
EP2167116A2 (en) * 2007-07-05 2010-03-31 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
US20100292444A1 (en) * 2007-07-05 2010-11-18 Novo Nordisk A/S Novel Prolactin Compounds
WO2009135031A1 (en) * 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
SG162687A1 (en) * 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
WO2012039954A2 (en) * 2010-09-08 2012-03-29 The Scripps Research Institute Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns
SG10201604554WA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US8906681B2 (en) 2011-08-02 2014-12-09 The Scripps Research Institute Reliable stabilization of N-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns
WO2014008404A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN105612183A (zh) * 2013-07-15 2016-05-25 诺和诺德股份有限公司 结合尿激酶纤溶酶原激活物的抗体
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
AU2019249427A1 (en) 2018-04-02 2020-10-29 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
US12187794B2 (en) * 2019-02-04 2025-01-07 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
AU2020358101A1 (en) 2019-10-02 2022-04-28 Alamab Therapeutics, Inc. Anto-connexin antibody formulations
US20240109965A1 (en) * 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239400B1 (en) 1986-03-27 1994-08-03 Medical Research Council Recombinant antibodies and methods for their production
EP1069185A1 (en) * 1998-04-03 2001-01-17 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ　スケール　バイオロジー　コーポレイション 形質転換された微生物によるメラニンの製造
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
EP1481010A2 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
HRP20140661T1 (hr) * 2007-03-22 2014-10-10 Genentech, Inc. Apoptotiäśka protutijela anti-ige koja vežu ige spojen s membranom
WO2010129904A1 (en) * 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same
CN103282495B (zh) * 2010-10-29 2017-06-09 第一三共株式会社 新的抗dr5抗体
WO2012170607A2 (en) * 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
MX2018006333A (es) * 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239400B1 (en) 1986-03-27 1994-08-03 Medical Research Council Recombinant antibodies and methods for their production
EP1069185A1 (en) * 1998-04-03 2001-01-17 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AMIT A.G. ET AL., SCIENCE, vol. 233, 1986, pages 747 - 753
BISCHOFF R.; KOLBE H.V.J., J. CHROMATOGR. B., vol. 662, 1994, pages 261 - 278
BLANCHE F. ET AL.: "Stabilization of recombinant adenovirus: site-directed mutagenesis of key asparagine residues in the hexon protein", ANAL. BIOCHEM., vol. 297, no. 1, 2001, pages 1 - 9, XP002962924 *
CHOTHIA C.; LESK A.M., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
HARRIS R.J.; KABAKOFF B.; MACCHI F.D.; SHEN F.J.; KWONG M.; ANDYA J.D. ET AL., J. CHROMATOGR. B., vol. 752, 2001, pages 233 - 245
PRESTA L. ET AL., THROMB. HAEMOST., vol. 85, 2001, pages 379 - 389
ROBINSON N.E.; ROBINSON A.B., PROC. NATL. ACAD. SCI. USA, vol. 98, 2001, pages 12409 - 12413
ROBINSON N.E.; ROBINSON A.B., PROC. NATL. ACAD. SCI. USA, vol. 98, 2001, pages 4367 - 4372
SCOTCHLER J.W.; ROBINSON A.B., ANAL. BIOCHEM., vol. 59, 1974, pages 319 - 322
See also references of EP1464702A4
TOMIZAWA H. ET AL.: "Stabilization of lysozyme against irreversible inactivation by alterations of the Asp-Gly sequences", PROTEIN ENG., vol. 8, no. 10, 1995, pages 1023 - 1028, XP002962925 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919086B2 (en) 2004-07-09 2011-04-05 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EP2898897A2 (en) 2004-07-09 2015-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EP2216046A2 (en) 2004-07-09 2010-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EP2314317A2 (en) 2004-07-09 2011-04-27 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
US7871613B2 (en) 2004-08-24 2011-01-18 Chugai Seiyaku Kabushiki Kaisha Adjuvant therapy with the use of anti-glypican 3 antibody
US7867734B2 (en) 2004-10-26 2011-01-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US20110033452A1 (en) * 2004-10-26 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-Glypican 3 Antibody Having Modified Sugar Chain
JP2006315964A (ja) * 2005-05-10 2006-11-24 Chugai Pharmaceut Co Ltd 抗体安定化方法
US10118959B2 (en) 2005-10-14 2018-11-06 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
US9102739B2 (en) 2005-10-14 2015-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
US12473375B2 (en) 2006-03-31 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP2009545325A (ja) * 2006-08-04 2009-12-24 アストラゼネカ アクチボラグ ＥｒｂＢ２に対する抗体
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9828429B2 (en) 2007-09-26 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12122840B2 (en) 2007-09-26 2024-10-22 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12116414B2 (en) 2007-09-26 2024-10-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9175091B2 (en) 2007-11-15 2015-11-03 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9890377B2 (en) 2008-04-11 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10066018B2 (en) 2009-03-19 2018-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9340615B2 (en) 2009-05-15 2016-05-17 Chugai Seiyaku Kabushiki Kaisha Anti-AXL antibody
WO2010131733A1 (ja) * 2009-05-15 2010-11-18 中外製薬株式会社 抗axl抗体
JP5669732B2 (ja) * 2009-05-15 2015-02-12 中外製薬株式会社 抗ａｘｌ抗体
US10005832B2 (en) 2009-05-29 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Method for treating a disease originated from receptor activation by EREG and TGFα
JP2013521769A (ja) * 2010-03-11 2013-06-13 ユセベ ファルマ ソシエテ アノニム 生物学的製剤：ヒト化アゴニスト抗ｐｄ−１抗体
CN103282495B (zh) * 2010-10-29 2017-06-09 第一三共株式会社 新的抗dr5抗体
WO2012057288A1 (ja) * 2010-10-29 2012-05-03 第一三共株式会社 新規抗ｄｒ５抗体
CN103282495A (zh) * 2010-10-29 2013-09-04 第一三共株式会社 新的抗dr5抗体
US9856321B2 (en) 2010-10-29 2018-01-02 Daiichi Sankyo Company, Limited Anti-DR5 antibodies, polynucleotides and methods
US9127070B2 (en) 2010-10-29 2015-09-08 Daiichi Sankyo Company, Limited Anti-DR5 antibodies, polynucleotides and methods
JP5918143B2 (ja) * 2010-10-29 2016-05-18 第一三共株式会社 新規抗ｄｒ５抗体
JP2016166180A (ja) * 2010-10-29 2016-09-15 第一三共株式会社 新規抗ｄｒ５抗体
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US10618965B2 (en) 2011-02-25 2020-04-14 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US11718678B2 (en) 2011-02-25 2023-08-08 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
WO2012133782A1 (ja) * 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
US10253100B2 (en) 2011-09-30 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
US11820793B2 (en) 2011-11-30 2023-11-21 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
US9556264B2 (en) 2011-12-28 2017-01-31 Chugai Seiyaku Kabushiki Kaisha Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient
WO2013100120A1 (ja) 2011-12-28 2013-07-04 中外製薬株式会社 ヒト化抗Epiregulin抗体および当該抗体を有効成分として含む癌治療剤
US12269876B2 (en) 2012-02-09 2025-04-08 Chugai Seiyaku Kabushiki Kaisha Modified Fc region of antibody
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
US10782300B2 (en) 2012-12-21 2020-09-22 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
WO2014208482A1 (ja) 2013-06-24 2014-12-31 中外製薬株式会社 ヒト化抗Ｅｐｉｒｅｇｕｌｉｎ抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
US11001643B2 (en) 2014-09-26 2021-05-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
US11053310B2 (en) 2015-12-04 2021-07-06 The Regents Of The University Of California Antibodies for the treatment of cancers
JP2019502670A (ja) * 2015-12-04 2019-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌の治療のための新規抗体
WO2019114804A1 (zh) 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 一种EGFRvIII抗体及其偶联物、制备方法和应用
JP2023531625A (ja) * 2020-06-19 2023-07-25 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ＣＤ３及びＦｏｌＲ１に結合する抗体
WO2024034638A1 (ja) * 2022-08-10 2024-02-15 協和キリン株式会社 抗ｆｇｆ２３抗体又は該抗体断片

Also Published As

Publication number Publication date
JP2009035532A (ja) 2009-02-19
US8084584B2 (en) 2011-12-27
US20060287508A1 (en) 2006-12-21
AU2002362197A1 (en) 2003-07-24
JPWO2003057881A1 (ja) 2005-05-19
EP3960855A1 (en) 2022-03-02
EP1464702A4 (en) 2005-09-21
EP3604523A1 (en) 2020-02-05
JP4063769B2 (ja) 2008-03-19
US20050171339A1 (en) 2005-08-04
EP1464702A1 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
WO2003057881A1 (en) Method of stabilizing protein
WO2004016286A3 (en) Pharmaceutical anti-tnf-alpha antibody formulation
AU2003248370A1 (en) Computational method for designing enzymes for incorporation of amino acid analogs into proteins
IL157446A0 (en) Increased recovery of active proteins
EP1176195A4 (en) METHOD OF REGULATING THE ACTIVITY OF AN IMMUNOLOGICALLY FUNCTIONAL MOLECULE
NO2017028I1 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2003102132A3 (en) Non-affinity purification of proteins
IL179617A0 (en) Method of stabilizing proteins
WO2004111216A3 (en) Phospholipase variants
WO2004047760A3 (en) Novel chemical compounds
AU2002236300A1 (en) Novel protein, gene encoding the same and method of using the same
WO2004048517A3 (en) Method for reducing or preventing modification of a polypeptide in solution
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
AU2003257536A1 (en) Method of stabilizing protein solution preparation
WO2005000862A3 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
AU2003290026A1 (en) Immunization of fish with plant-expressed recombinant proteins
AU2002245255A1 (en) Regulation of target protein activity through modified proteins
DE60130922D1 (de) Peptide mit inhibierender Aktivität zur Produktion von Stickstoffmonoxid
WO2003055440A8 (en) Compositions and methods for the treatement of immune related diseases
AU2003202817A1 (en) Manufacturing method of recombinant protein in yeast by the use of secretory type vector
AU2003235975A1 (en) Method of decomposing protein with sulfonic acid compound
WO2002062964A3 (en) Ap1 amine oxidase variants
WO2004006864A3 (en) Methods and compositions for the enhancement of wound healing
WO2001009292A3 (en) Sentrin-specific human proteases senp1-3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003558175

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2002792048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002792048

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002792048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10500184

Country of ref document: US